Hepatitis delta in HIV-infected individuals in Europe

Soriano, Vincent; Grint, Daniel; Monforte, Antonella d’Arminio; Horban, Andrzéj; Leen, Clifford; Poveda, Eva; Antúnes, Francisco; Wit, Stéphane De; Lundgren, Jens D.; Rockstroh, Jürgen K.; Peters, Lars

doi:10.1097/qad.0b013e32834babb3

Cited by 87 publications

(88 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, 14% of positive HDV screening tests were false-positive. After the exclusion of these patients, 63% of HDVpositive patients had a detectable HDV viral load, which was lower than the proportion found in the EuroSIDA study 4 . Although the main reason for this difference remains unclear, the unselected nature of our study population, in which all patients were screened for HBV and HDV infection independently of clinical manifestations or laboratory abnormalities, might have played an important role.…”

Section: Discussioncontrasting

confidence: 65%

See 1 more Smart Citation

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients

Béguelin

Moradpour

Sahli

et al. 2017

Journal of Hepatology

113

119

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 65%

“…Of a selected sample of 422 hepatitis B surface antigen (HBsAg) carriers in the EuroSIDA collaboration, 61 (14%) were coinfected with HDV 4 . The prevalence of anti-HDV antibodies seems even higher in HIV/HBV-coinfected patients from SSA, reaching 25% in GuineaBissau 5 .…”

Section: Introductionmentioning

confidence: 99%

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients

Béguelin

Moradpour

Sahli

et al. 2017

Journal of Hepatology

113

119

View full text Add to dashboard Cite

“…Also other studies in Africa have showed varying prevalence rates of HDV ranging from 0-50% in different countries [18][19][20] . Similarly in the developed countries, high anti-HDV prevalence's of 10-15% have been documented in recent studies 1,21,22 . Reasons for the variations in the prevalence of HDV exposure or infection are not clear.…”

Section: Discussionmentioning

confidence: 99%

“…Reasons for the variations in the prevalence of HDV exposure or infection are not clear. This could be a result of modes of transmission whereby in some of these countries there could be higher rates of IVD use 21,22 . In addition, we have confirmed earlier findings that male gender was significantly associated with anti HDV antibody positivity 23,24 .…”

Section: Discussionmentioning

confidence: 99%

Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda

et al. 2017

View full text Add to dashboard Cite

Background: Co-infection with hepatitis B (HBV) and hepatitis D (HDV) is common among human immunodeficiency virus (HIV) infected individuals in developing countries and it aggressively accelerates progression of liver disease to cirrhosis and other complications. There is scarcity of data on HDV in sub-Saharan Africa .We investigated the sero-prevalence and factors associated with HDV antibody among HIV/HBV co-infected patients attending a large urban HIV clinic in Uganda. Methods: We screened 189 HIV/HBV co-infected individuals for anti-HDV immunoglobulin G (IgG) and performed logistic regression to determine the associated factors. Socio-demographic, clinical data, immunological status, and liver fibrosis (as determined by the Aspartate transaminase to platelet ratio index and transient elastography) were included. Results: Participants were predominately young and of sound immunologic status (median age 40 years, median CD4 440 cells/µl). 98% were on ART regimens containing anti-HBV active medications (95.2% were on TDF/3TC while 4.8% on 3TC containing regimen). Median duration on ART was 36 months . Anti-HDV was detected in 6/198, 3.2% (95% CI 1.14-6.92%), associated with male gender and a duration of more than 5 years since HIV diagnosis. Conclusions:The sero-prevalence of HDV antibodies among the HIV/HBV co-infected patients is low in a Ugandan urban cohort.

show abstract

“…HBV reactivation is more likely to occur in HIV patients even after HBs antibody response (1,8). Hepatitis delta virus (HDV) represents a risk factor for the severity of chronic hepatitis B, but was not associated with progression to the stage of acquired immunodeficiency syndrome (AIDS) (9).…”

Section: Introductionmentioning

confidence: 99%

Characteristics of Hepatitis B Co-infection and Disease Evolution in HIV-Positive Paediatric Patients in Romania

Arbune¹,

Georgescu²

2013

Balkan Med J

View full text Add to dashboard Cite

Background: Infection with hepatitis B virus (HBV) contributes to morbidity and mortality in people living with human immunodeficiency virus (HIV). Aims:The aim of the present study is to assess the influence of HBV co-infection in clinical characteristics and disease evolution among nosocomial HIV infected youth in Romania.Study Design: Retrospective study. Methods:We assessed HBsAg in 179 young people with nosocomial paediatric HIV infection. Demographic data, ALAT level, CD4-count, HIV-RNA, antiretroviral therapy and clinical behaviour were all statistically compared in patients who were HIV mono-infected and HBV-co-infected. Results:The characteristics of patients are as follows: sex ratio M/F: 55.3%, AIDS category 88%, median nadir CD4-count 126/mm 3 . The prevalence of persistent HBsAg was 44.6%. The mortality rate was 11.1%, but no correlation with HBsAg was found. An average of three antiretroviral combinations is experienced by 97.7% of patients, including Lamivudine for over 5 years in 76% of cases and Tenofovir/Emtricitabine in 16.75% of patients. Patients under antiretroviral therapy achieved 53.07% sustained undetectable HIV-RNA and 40.78% restored immunity CD4-count >500/mm 3 . ALAT enzyme was found to be high in 54.75% of patients.Conclusion: During our research, we noticed that HBsAg was elevated in young people with HIV in Romania. Mortality rate was not statistically correlated to HBsAg. High ALAT levels are related with HBV, HDV co-infections, virological failure to antiretroviral treatment and the risk of death.

show abstract

Hepatitis delta in HIV-infected individuals in Europe

Cited by 87 publications

References 31 publications

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients

Low sero-prevalence of hepatitis delta antibodies in HIV/ hepatitis B co-infected patients attending an urban HIV clinic in Uganda

Characteristics of Hepatitis B Co-infection and Disease Evolution in HIV-Positive Paediatric Patients in Romania

Contact Info

Product

Resources

About